Supplementary Table 3. Definitions of analysis sets

Analysis set	Definitions	Data presented
Randomized set	Randomized set comprised patients who were assigned a randomization number.	Baseline patient characteristics
Full analysis set (FAS)	FAS comprised patients who received at least one dose of the study drug after randomization and had at least one HbA1c result during treatment period.	All efficacy endpoints except those of lipid profile and of blood pressure. Treatment compliance
Per-protocol set (PPS)	Among patients included in the FAS, those who completed 24-week treatment period without major protocol deviations were included in the PPS.	All efficacy endpoints except those of lipid profile and of blood pressure. PPS was the main analysis set for efficacy evaluation.
Modified FAS 1 Modified PPS 1	Among patients included in the FAS or PPS, those with any change in their antihyperlipidemic medication(s) during the study period were excluded and the remaining patients composed the modified FAS 1 or modified PPS 1, respectively.	The endpoints of lipid profile
Modified FAS 2 Modified PPS 2	Among patients included in the FAS or PPS, those with any change in their antihypertensive medication(s) during the study period were excluded and the remaining patients composed the modified FAS 2 or modified PPS 2, respectively.	The endpoints of blood pressure
Safety analysis set	Safety analysis set included patients who received at least one dose of the study drug after randomization and had any post-randomization safety follow-up data.	Exposure to the study drugs and metformin Safety endpoints

HbA1c, glycosylated hemoglobin.